 |
PDBsum entry 4xfs
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Cytokine
|
|
|
Title:
|
|
Structure of il-18 ser mutant i
|
|
Structure:
|
|
Interleukin-18. Chain: a, b. Synonym: il-18,iboctadekin,interferon gamma-inducing factor,ifn- gamma-inducing factor,interleukin-1 gamma,il-1 gamma. Engineered: yes. Mutation: yes
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Gene: il18, igif, il1f4. Expressed in: escherichia coli. Expression_system_taxid: 469008.
|
|
Resolution:
|
|
|
1.91Å
|
R-factor:
|
0.181
|
R-free:
|
0.229
|
|
|
Authors:
|
|
B.E.Krumm,X.Meng,Y.Xiang,J.Deng
|
|
Key ref:
|
|
B.Krumm
et al.
(2015).
Crystallization of interleukin-18 for structure-based inhibitor design.
Acta Crystallogr F Struct Biol Commun,
71,
710-717.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
29-Dec-14
|
Release date:
|
10-Jun-15
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
Q14116
(IL18_HUMAN) -
Interleukin-18 from Homo sapiens
|
|
|
|
Seq:
Struc:
|
|
|
|
193 a.a.
156 a.a.*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
 |
CATH domain |
|
|
*
PDB and UniProt seqs differ
at 5 residue positions (black
crosses)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Acta Crystallogr F Struct Biol Commun
71:710-717
(2015)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Crystallization of interleukin-18 for structure-based inhibitor design.
|
|
B.Krumm,
X.Meng,
Y.Xiang,
J.Deng.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
Interleukin-18 (IL-18) is a pleiotropic pro-inflammatory cytokine belonging to
the IL-1 superfamily. IL-18 plays an important role in host innate and acquired
immune defense, with its activity being modulated in vivo by its naturally
occurring antagonist IL-18 binding protein (IL-18BP). Recent crystal structures
of human IL-18 (hIL-18) in complex with its antagonist or cognate receptor(s)
have revealed a conserved binding interface on hIL-18 representing a promising
drug target. An important step in this process is obtaining crystals of apo
hIL-18 or hIL-18 in complex with small-molecule inhibitors, preferably under low
ionic strength conditions. In this study, surface-entropy reduction (SER) and
rational protein design were employed to facilitate the crystallization of
hIL-18. The results provide an excellent platform for structure-based drug
design.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Links
